Mucolytics, expectorants, and mucokinetic medications

Area of Science:

• Pulmonary Medicine
• Biophysics
• Pharmacology

Background:

• Airways are protected by mucus gel and periciliary fluid, crucial for clearing bacteria and preventing irritation.
• Mucus properties depend on mucins (MUC5AC, MUC5B), forming a barrier against pathogens and irritants.
• In cystic fibrosis, airways fill with inflammatory DNA and actin polymers (pus) instead of mucus, leading to damage.

Purpose of the Study:

• To review the role of airway mucus and the effectiveness of mucoactive medications.
• To evaluate expectorants, mucolytics, and mucokinetics for airway diseases.
• To identify potential therapeutic strategies for managing airway pus.

Main Methods:

• Literature review of mucoactive drug classes and their mechanisms.
• Analysis of evidence for expectorants (guaifenesin, hyperosmolar saline, mannitol).
• Assessment of mucolytics (N-acetylcysteine) and DNA/actin-depolymerizing agents (dornase alfa, thymosin beta(4)).
• Evaluation of mucokinetic agents (aerosol surfactant).

Main Results:

• Expectorants like guaifenesin lack evidence of efficacy and may pose risks.
• Hyperosmolar saline and mannitol are used as expectorants in cystic fibrosis.
• Mucolytics like N-acetylcysteine show no proven benefit and can cause epithelial damage.
• DNA-active drugs (dornase alfa) and potentially actin-depolymerizing drugs may help break down airway pus.
• Aerosol surfactant is a promising mucokinetic agent.

Conclusions:

• Many mucoactive medications lack proven efficacy or carry risks for airway diseases.
• Targeting airway pus with DNA-active or actin-depolymerizing agents shows potential.
• Mucokinetic agents, particularly aerosol surfactant, offer promising therapeutic avenues.